Pharmafile Logo
Pharmafocus logo
Advanced Search

Nice extends price-negotiation talks for PTC’ muscle wasting drug

May 4, 2016
Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, NICE, PTC Therapeutics, Translarna, market access, regulation

UK regulators have extended the cost negotiation talks with PTC Therapeutics (Nasdaq: PTCT) by a week for the drug to …

News

Pfizer revenue jumps 20%; ups FY16 outlook

May 4, 2016
Research and Development, Sales and Marketing Pfizer, Q1, earnings, results, revenue, sales

US pharma giant Pfizer (NYSE: PFE) reported a 20% jump in first-quarter revenue boosted by performance of its new cancer …

News

Sun Pharma to partner with ICGEB to develop novel Dengue treatment

May 4, 2016
Research and Development Dengue fever, Sun Pharma, collaboration, dengue, development, drug, icgeb, international centre for genetic engineering and biotechnology, partnership, sun pharmaceutical

Sun Pharmaceuticals (BSE: 85715) and the International Centre for Genetic Engineering and Biotechnology (ICGEB) are set to team up to …

News

US biotech company to try resurrect the clinically dead

May 4, 2016
Research and Development US, bioquark, biotech, brain, central nervous system, clinically dead, dead, patients, ressurect

A US biotech firm has announced plans for a Phase I trial that will see them attempt to bring brain-dead …

News

Pfizer joins the race, bids for Medivation – Reports

May 4, 2016
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi

US pharma giant Pfizer (NYSE: PFE) is rumoured to have joined the list of suitors vying for the Medivation (Nasdaq: …

News
amgen_flag

FDA grants priority review for Amgen leukaemia drug

May 4, 2016
Research and Development, Sales and Marketing Amgen, FDA, blincyto, leukaemia, lymphoblastic leukaemia, paediatric

Amgen has announced that the US Food and Drug Administration (FDA) has granted priority review status for the supplemental Biologics …

News
ims_health_quintiles

Quintiles to merge with IMS Health

May 3, 2016
Medical Communications, Research and Development, Sales and Marketing IMS Health, Quintiles, merger

IMS Health (NYSE: IMS) and Quintiles (NYSE: Q) have announced that a definitive merger agreement has been made between the …

News
parks

New CFO at Mylan

May 3, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mylan, cfo, kenneth parks

Mylan has announced the appointment of Kenneth S. Parks as its new chief financial officer, effective June 6 2016. Parks …

Appointment
google

Google files for US patent to electronic eye lens

May 3, 2016
Manufacturing and Production, Research and Development Alphabet, google, lens, patent, research

Alphabet Inc (Nasdaq: GOOG) has filed a patent application for a device that can be implanted in the eye to …

News
biogen_austria_238

EMA recommends Biogen’s MS treatment Zinbryta

May 3, 2016
Research and Development, Sales and Marketing Biogen, CHMP, EMA, daclizumab, zinbryta

The Committee for Medicinal Products for Human Use (CMHP) has recommended the granting of a marketing authorisation for Zinbryta (daclizumab) …

News
vaccination

In-depth: MSF takes on Pfizer, GSK

May 3, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Doctors Without Borders, GSK, Pfizer, analysis, medicins sans frontieres, patents, pneumonia

Medicins Sans Frontieres (MSF) recently stepped up their campaign to make the pneumonia vaccine more available in developing countries. Appearing …

Feature

France to push for drug price control regulations at upcoming G7 summit

May 3, 2016
Manufacturing and Production Drug pricing, France, drug prices, g7 summit, hollande, irreversible, medicines, pharmaceutical, prices

France will urge its fellow G7 partners to introduce strict and final new limits to control the prices of new …

News
stocks1

Weekly Movers: Neuren Pharma, Eli Lilly, Gilead Sciences…

May 3, 2016
Manufacturing and Production

Corporate result announcements remained the key focus as well as the primary drivers for stock movements this week as the …

Feature
regeneron

Regeneron says trial drug for osteoarthritis pain meets primary endpoint in Phase II trials

May 3, 2016
Manufacturing and Production, Research and Development Phase II, Regeneron Pharmaceuticals, drug trial, osteoarthritis, phase III

Regeneron Pharmaceuticals (Nasdaq: REGN) said mid-stage trials for its drug candidate to treat osteoarthritis pain med its primary endpoint. The …

News
bill_ackman

Big investor hits back at critics as Valeant’s war of words gathers pace

May 3, 2016
Manufacturing and Production, Sales and Marketing Valeant, ackman, allegations, buffett, practices, price gouging, price rises, scandal

Valeant have hit the mainstream news again after key investor Bill Ackman mounted a robust defence of the company, ruling …

News
v2_crestor_10_mg

Allergan launches Crestor generic in the US

May 3, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, AstraZeneca, Crestor, FDA, FDA Approval, cholesterol, generic, patent, patent expiry, sales

Allergan has received FDA approval on the generic version of AstraZeneca’s high cholesterol drug, Crestor (rosuvastatin), and has become the …

News
mylan_building

Mylan Q1 revenue up 17%, maintains FY view

May 3, 2016
Manufacturing and Production, Sales and Marketing Financial, Mylan, Q1, results, revenue, sales

Pharma firm Mylan NV (Nasdaq: MYL) on Tuesday reported a 17% rise in first-quarter revenue and said it maintains its …

News
novartis_afinitor

Afinitor receives EU recommendation to treat rare lung cancer

April 29, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Afinitor, Novartis

Novartis has received a recommendation from the Committee for Medicinal Products for Human Use at the European Medicines Agency for …

News
sanofi_hq__boetie_hall

Board at Medivation unanimously reject Sanofi bid

April 29, 2016
Medical Communications, Sales and Marketing Medivation, Sanofi, board, hostile, rejection, takeover

The board at Medivation has unanimously rejected the $9.8 billion takeover bid from Sanofi. They declare that Sanofi’s bid of …

News
novartis_horsham_site_closure

Novartis’ two cancer drugs get NICE backing as combination treatment for skin cancer

April 29, 2016
Medical Communications NICE, Novartis, combination therapy, regulation, skin cancer

The National Institute for Health and Care Excellence (NICE) on Friday backed a combination therapy for skin cancer comprising two …

News
The Gateway to Local Adoption Series

Latest content

Japanese pharma outsources earlier as peptide development challenges grow

April 29, 2026

Study suggests phospholipid therapy may impact fatty liver disease outcomes

April 29, 2026

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026